Zevra Therapeutics, Inc.
ZVRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $26,063 | $25,881 | $20,401 | $12,043 |
| % Growth | 0.7% | 26.9% | 69.4% | – |
| Cost of Goods Sold | $1,553 | $12,379 | $1,345 | $1,366 |
| Gross Profit | $24,510 | $13,502 | $19,056 | $10,677 |
| % Margin | 94% | 52.2% | 93.4% | 88.7% |
| R&D Expenses | $3,432 | $3,433 | $3,258 | $9,914 |
| G&A Expenses | $0 | $0 | $0 | $1,604 |
| SG&A Expenses | $16,935 | $20,782 | $19,545 | $16,125 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $14,521 |
| Other Operating Expenses | $0 | $60,326 | $1,615 | $54 |
| Operating Expenses | $20,367 | $84,541 | $24,418 | $26,093 |
| Operating Income | $4,143 | -$71,039 | -$5,362 | -$15,416 |
| % Margin | 15.9% | -274.5% | -26.3% | -128% |
| Other Income/Exp. Net | -$5,120 | $147,945 | $3,445 | -$4,952 |
| Pre-Tax Income | -$977 | $76,906 | -$1,917 | -$20,368 |
| Tax Expense | $433 | $2,199 | $1,182 | $15,371 |
| Net Income | -$1,410 | $74,707 | -$3,099 | -$35,739 |
| % Margin | -5.4% | 288.7% | -15.2% | -296.8% |
| EPS | -0.01 | 1.364 | -0.057 | -0.67 |
| % Growth | -100.7% | 2,479.9% | 91.4% | – |
| EPS Diluted | -0.01 | 1.364 | -0.057 | -0.67 |
| Weighted Avg Shares Out | 55,952 | 54,781 | 54,096 | 53,671 |
| Weighted Avg Shares Out Dil | 55,952 | 56,325 | 54,096 | 53,671 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $543 | -$73 |
| Interest Expense | $2,051 | $2,009 | $1,969 | $2,194 |
| Depreciation & Amortization | $392 | $1,651 | $1,649 | $1,648 |
| EBITDA | $1,466 | $80,566 | $1,701 | -$16,526 |
| % Margin | 5.6% | 311.3% | 8.3% | -137.2% |